First‐line R‐CVP Versus R‐CHOP Induction Immunochemotherapy for Indolent Lymphoma With Rituximab Maintenance. A Multicentre, Phase III Randomized Study by the Polish Lymphoma Research Group PLRG4

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.16264
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2016English

Rituximab Maintenance for Patients With Diffuse Large B-Cell Lymphoma in First Complete Remission: Results From a Randomized Hovon-Nordic Lymphoma Group Phase Iii Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

ROBUST: First Report of Phase III Randomized Study of Lenalidomide/R-Chop (R2 -CHOP) vs Placebo/R-Chop in Previously Untreated ABC-type Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Da-Epoch-R Versus R-Chop in High Risk DLBCL Patients: Analysis of the Czech Lymphoma Study Group (Clsg)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Robust: Phase Iii Randomized Study of Lenalidomide/R-Chop vs Placebo/R-Chop in Untreated Abc-Type Diffuse Large B-Cell Lymphoma and Feasibility of Cell of Origin Subtyping

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

First-Line Treatment of Inhl or MCL Patients With Br or R-Chop/R-Cvp: Results of the Bright 5-Year Follow-Up Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Immunochemotherapy With Obinutuzumab or Rituximab in Previously Untreated Follicular Lymphoma in the Randomised Phase Iii Gallium Study: Analysis by Chemotherapy Regimen

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Bendamustine-Rituximab (Br) Versus R-Chop as Upfront Therapy for Indolent B-Cell Lymphomas: A Comparative, Population-Based Analysis

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Prospective Clinical Study of R-CMD Therapy for Indolent B Cell Lymphoma and Mantle Cell Lymphoma From the Hokuriku Hematology Oncology Study Group

Medical Oncology
MedicineCancer ResearchOncologyHematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy